Bacterial Vaginosis Global Market Report 2025

The bacterial vaginosis market size has grown strongly in recent years. It will grow from $3.03 billion in 2024 to $3.32 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historic period can be attributed to the increased adoption of point-of-care diagnostics, the expansion of e-commerce, a rise in risky sexual behaviors, the growth of STI vaccination, and improved healthcare access.

The bacterial vaginosis market size is expected to see strong growth in the next few years. It will grow to $4.75 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to the increasing prevalence of bacterial vaginosis, rising demand for functional foods, a growing incidence of STIs, the increasing prevalence of women’s health conditions, and greater awareness of menopause. Key trends expected during this period include the integration of artificial intelligence (AI) in diagnostics, the adoption of probiotics, advancements in home-based STI testing, and the use of sustainable materials in women's health devices.

The rising incidence of sexually transmitted infections (STIs) is expected to drive the growth of the bacterial vaginosis market. STIs are infections primarily transmitted through sexual contact and can be caused by bacteria, viruses, or parasites. Several factors contribute to the increasing prevalence of STIs, including unprotected sex, multiple partners, lack of awareness, and antibiotic resistance. Bacterial vaginosis increases vulnerability to STIs by disrupting the vaginal bacterial balance, making it easier for infections such as HIV and chlamydia to take hold. For example, in March 2024, the European Centre for Disease Prevention and Control (ECDC), a Sweden-based government agency, reported a significant rise in STI cases in 2022 compared to the previous year, with gonorrhea increasing by 48%, syphilis by 34%, and chlamydia by 16%. As a result, the growing incidence of STIs is fueling the expansion of the bacterial vaginosis market.

Leading companies in the bacterial vaginosis market are developing innovative solutions such as multiplexed polymerase chain reaction (PCR) tests to accelerate diagnosis and treatment. A multiplexed PCR test enables the simultaneous amplification and detection of multiple target DNA or RNA sequences within a single experiment. For instance, in November 2022, Cepheid, a US-based biotechnology research company, launched the Xpert Xpress Multiplex Vaginal Panel (MVP). This test delivers rapid results in under 60 minutes and detects three vaginal infections bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis (TV) from a single sample. Designed for both clinician-collected and self-collected swabs, the test utilizes automated real-time PCR technology to improve diagnostic accuracy and treatment outcomes. Its versatility allows for use in various clinical settings, ensuring efficient and precise detection of vaginal infections.

In July 2024, Evofem Biosciences, a US-based biopharmaceutical company, acquired the US commercial women's health specialty business from Lupin Limited for $84 million. This acquisition is intended to expand Evofem Biosciences' portfolio in women's health by adding an FDA-approved treatment for bacterial vaginosis and trichomoniasis. Lupin Limited, an India-based pharmaceutical company, specializes in the development and distribution of a wide range of healthcare products, including women's health specialty treatments.

Major players in the bacterial vaginosis market are Pfizer Inc., Merck & Co. Inc., Merck KGaA, Bayer AG, Sanofi SA, Thermo Fisher Scientific, Becton Dickinson, Viatris Inc., Otsuka Pharmaceutical, LabCorp, Quest Diagnostics, Organon & Co., UT Southwestern Medical Center, Hologic Inc., bioMérieux SA, Shionogi & Company Limited, Melinta Therapeutics Inc., Evofem Biosciences, Gedea Biotech, Fleurstat, and Medical Diagnostic Laboratories.

North America was the largest region in the bacterial vaginosis market in 2024. The regions covered in bacterial vaginosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bacterial vaginosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bacterial vaginosis (BV) is a prevalent vaginal infection resulting from an imbalance in naturally occurring bacteria. This imbalance leads to a reduction in lactobacilli and an overgrowth of anaerobic bacteria. Common symptoms include a fishy odor, thin grayish-white discharge, and vaginal discomfort, though some cases may be asymptomatic.

The primary categories of bacterial vaginosis include point-of-care testing, laboratory testing, and others. Point-of-care testing (POCT) involves medical diagnostic tests conducted at or near the patient’s location, delivering rapid results for immediate clinical decision-making. Various product categories include those designed for individuals under 15 years, those aged 15-45 years, and others. Applications consist of antibiotics and alternative treatments, utilized by different end users such as hospitals, home care settings, specialty clinics, and others.

The bacterial vaginosis market research report is one of a series of new reports that provides bacterial vaginosis market statistics, including the bacterial vaginosis industry's global market size, regional shares, competitors with a bacterial vaginosis market share, detailed bacterial vaginosis market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial vaginosis industry. This bacterial vaginosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bacterial vaginosis market includes revenues earned by entities by providing services such as wet mount microscopy, pH testing, and dietary recommendations. The market value includes the value of related goods sold by the service provider or included within the service offering. The bacterial vaginosis (BV) market consists of sales of oral and topical antibiotics, probiotics, pH balancers, gels, and creams. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.